ATE510824T1 - Kondensierte verbindungen, die den vanilloid- rezeptor-subtyp-1 hemmen - Google Patents

Kondensierte verbindungen, die den vanilloid- rezeptor-subtyp-1 hemmen

Info

Publication number: ATE510824T1
Authority: AT; Austria
Prior art keywords: inhibit; compounds; receptor subtype; vanilloid receptor; condensed compounds
Prior art date: 2003-06-12

Application number

AT08166079T

Other languages

English (en)

Inventor

Arthur Gomtsyan

Erol Bayburt

Chih-Hung Lee

John Koenig

Robert Schmidt

Kirill Lukin

Gilles Chambournier

Margaret Hsu

Robert Leanna

Russel Cink

Original Assignee

Abbott Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-06-12

Filing date

2004-06-10

Publication date

2011-06-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33555102&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE510824(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-06-12 Priority claimed from US10/459,925 external-priority patent/US7015233B2/en

2004-06-09 Priority claimed from US10/864,068 external-priority patent/US7375126B2/en

2004-06-10 Application filed by Abbott Lab filed Critical Abbott Lab

2011-06-15 Application granted granted Critical

2011-06-15 Publication of ATE510824T1 publication Critical patent/ATE510824T1/de

Links

150000001875 compounds Chemical class 0.000 title abstract 5
108010025083 TRPV1 receptor Proteins 0.000 title abstract 2
102100029613 Transient receptor potential cation channel subfamily V member 1 Human genes 0.000 title 1
208000004454 Hyperalgesia Diseases 0.000 abstract 1
208000035154 Hyperesthesia Diseases 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
206010046543 Urinary incontinence Diseases 0.000 abstract 1
230000002757 inflammatory effect Effects 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Materials For Photolithography (AREA)

AT08166079T 2003-06-12 2004-06-10 Kondensierte verbindungen, die den vanilloid- rezeptor-subtyp-1 hemmen ATE510824T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US10/459,925 US7015233B2 (en)	2003-06-12	2003-06-12	Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
US10/864,068 US7375126B2 (en)	2003-06-12	2004-06-09	Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Publications (1)

Publication Number	Publication Date
ATE510824T1 true ATE510824T1 (de)	2011-06-15

Family

ID=33555102

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT04754996T ATE411982T1 (de)	2003-06-12	2004-06-10	Kondensierte verbindungen, die den vanilloid receptor subtype 1 (vr1)-rezeptor hemmen
AT08166079T ATE510824T1 (de)	2003-06-12	2004-06-10	Kondensierte verbindungen, die den vanilloid- rezeptor-subtyp-1 hemmen

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT04754996T ATE411982T1 (de)	2003-06-12	2004-06-10	Kondensierte verbindungen, die den vanilloid receptor subtype 1 (vr1)-rezeptor hemmen

Country Status (20)

Country	Link
EP (2)	EP2017265B1 (de)
JP (2)	JP4857113B2 (de)
KR (2)	KR101138216B1 (de)
CN (1)	CN102617464A (de)
AT (2)	ATE411982T1 (de)
AU (2)	AU2004247721C1 (de)
BR (1)	BRPI0411116A (de)
CA (2)	CA2526872C (de)
CY (2)	CY1108713T1 (de)
DE (1)	DE602004017329D1 (de)
DK (2)	DK1658269T3 (de)
ES (1)	ES2318308T3 (de)
IL (4)	IL172457A (de)
MX (1)	MXPA05013550A (de)
NZ (3)	NZ543713A (de)
PL (2)	PL2017265T3 (de)
PT (2)	PT2017265E (de)
SI (2)	SI1658269T1 (de)
TW (3)	TWI394569B (de)
WO (1)	WO2004111009A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005089380A2 (en)	2004-03-16	2005-09-29	The Regents Of The University Of California	Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
EP1608319A4 (de)	2003-04-03	2007-02-28	Univ California	Verbesserte hemmer für lösliche epoxidhydrolase
CA2584342C (en)	2004-10-20	2013-04-30	The Regents Of The University Of California	Improved inhibitors for the soluble epoxide hydrolase
US7612200B2 (en)	2004-12-07	2009-11-03	Locus Pharmaceuticals, Inc.	Inhibitors of protein kinases
EP1828169A2 (de)	2004-12-07	2007-09-05	Locus Pharmaceuticals, Inc.	Harnstoffinhibitoren von map-kinasen
KR20080064972A (ko)	2005-10-07	2008-07-10	그렌마크 파머수티칼스 에스. 아.	치환된 벤조융합 유도체 및 이의 바닐로이드 수용체리간드로서의 용도
CN101346128B (zh) *	2005-10-25	2013-10-02	雅培制药有限公司	包含低水溶解度药物的配方及其使用方法
JP2009513659A (ja)	2005-10-28	2009-04-02	アボット・ラボラトリーズ	Ｔｒｐｖ１受容体を阻害するインダゾール誘導体
AR059826A1 (es) *	2006-03-13	2008-04-30	Univ California	Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
JP2009534399A (ja) *	2006-04-18	2009-09-24	アボット・ラボラトリーズ	バニロイド受容体サブタイプ１型（ｖｒ１）の拮抗薬およびその使用
WO2009081222A1 (en)	2007-12-21	2009-07-02	Glenmark Pharmaceuticals, S.A.	Substituted tricyclic pyridine or pyrimidine vanilloid receptor ligands
CN101925575B (zh)	2008-01-28	2014-06-18	株式会社爱茉莉太平洋	作为香草酸受体拮抗剂的化合物、其异构体或其药物学可接受的盐、及包含这些化合物的药物组合物
CN102137851B (zh)	2008-07-02	2014-08-27	株式会社爱茉莉太平洋	作为香草素受体拮抗剂的化合物、其异构体或其药学可接受的盐以及包含它们的药物组合物
EP2352726A1 (de) *	2008-10-17	2011-08-10	Abbott Laboratories	Trpv1-antagonisten
US9296693B2 (en)	2010-01-29	2016-03-29	The Regents Of The University Of California	Acyl piperidine inhibitors of soluble epoxide hydrolase
BR112013029201B1 (pt)	2011-05-13	2022-08-09	Array Biopharma Inc	Compostos de pirrolidinil ureia e pirrolidinil tioureia, seu processo de preparação, seu uso e composições farmacêuticas
US9375005B2 (en) *	2012-05-09	2016-06-28	Bayer Cropscience Ag	5-halogenopyrazole indanyl carboxamides
WO2014078331A1 (en)	2012-11-13	2014-05-22	Array Biopharma Inc.	N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9809578B2 (en)	2012-11-13	2017-11-07	Array Biopharma Inc.	Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors
CN104781255B (zh)	2012-11-13	2017-10-24	阵列生物制药公司	作为trka激酶抑制剂的n‑吡咯烷基、n’‑吡唑基‑脲、硫脲、胍和氰基胍化合物
WO2014078322A1 (en)	2012-11-13	2014-05-22	Array Biopharma Inc.	Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078328A1 (en)	2012-11-13	2014-05-22	Array Biopharma Inc.	N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9790210B2 (en)	2012-11-13	2017-10-17	Array Biopharma Inc.	N-(monocyclic aryl),N'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078372A1 (en)	2012-11-13	2014-05-22	Array Biopharma Inc.	Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078408A1 (en)	2012-11-13	2014-05-22	Array Biopharma Inc.	Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078378A1 (en)	2012-11-13	2014-05-22	Array Biopharma Inc.	Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
PT2920166T (pt)	2012-11-13	2017-01-31	Array Biopharma Inc	Compostos de ureia bicíclica, tioureia, guanidina e cianoguanidina úteis para o tratamento de dor
CA2949160C (en)	2014-05-15	2023-03-21	Array Biopharma Inc.	1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor
US20210323913A1 (en) *	2016-04-29	2021-10-21	Board Of Regents, The University Of Texas System	Sigma receptor binders
DE102022104759A1 (de)	2022-02-28	2023-08-31	SCi Kontor GmbH	Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW536734B (en) *	2000-07-31	2003-06-11	Clariant Int Ltd	Process for manufacturing a microelectronic device
WO2003014064A1 (en) *	2001-07-31	2003-02-20	Bayer Healthcare Ag	Naphthylurea and naphthylacetamide derivatives as vanilloid receptor 1 (vr1) antagonists
JP2003192587A (ja) *	2001-12-26	2003-07-09	Bayer Ag	尿素誘導体
DE60325834D1 (de) *	2002-02-20	2009-03-05	Abbott Lab	Kondensierte azabicyclischeverbindungen als inhibitoren des vanilloid-rezeptors 1 (vr1)
GB0206876D0 (en) *	2002-03-22	2002-05-01	Merck Sharp & Dohme	Therapeutic agents
WO2003097586A1 (en) *	2002-05-17	2003-11-27	Janssen Pharmaceutica N.V.	Aminotetralin-derived urea modulators of vanilloid vr1 receptor

2004
- 2004-06-10 MX MXPA05013550A patent/MXPA05013550A/es active IP Right Grant
- 2004-06-10 PL PL08166079T patent/PL2017265T3/pl unknown
- 2004-06-10 CN CN2012100573625A patent/CN102617464A/zh active Pending
- 2004-06-10 BR BRPI0411116-8A patent/BRPI0411116A/pt not_active IP Right Cessation
- 2004-06-10 NZ NZ543713A patent/NZ543713A/en not_active IP Right Cessation
- 2004-06-10 AT AT04754996T patent/ATE411982T1/de active
- 2004-06-10 EP EP08166079A patent/EP2017265B1/de not_active Expired - Lifetime
- 2004-06-10 SI SI200430995T patent/SI1658269T1/sl unknown
- 2004-06-10 KR KR1020057023829A patent/KR101138216B1/ko not_active Expired - Fee Related
- 2004-06-10 EP EP04754996A patent/EP1658269B1/de not_active Expired - Lifetime
- 2004-06-10 ES ES04754996T patent/ES2318308T3/es not_active Expired - Lifetime
- 2004-06-10 AU AU2004247721A patent/AU2004247721C1/en not_active Ceased
- 2004-06-10 JP JP2006533722A patent/JP4857113B2/ja not_active Expired - Fee Related
- 2004-06-10 DK DK04754996T patent/DK1658269T3/da active
- 2004-06-10 CA CA2526872A patent/CA2526872C/en not_active Expired - Fee Related
- 2004-06-10 CA CA2756058A patent/CA2756058A1/en not_active Abandoned
- 2004-06-10 PL PL04754996T patent/PL1658269T3/pl unknown
- 2004-06-10 AT AT08166079T patent/ATE510824T1/de active
- 2004-06-10 DE DE602004017329T patent/DE602004017329D1/de not_active Expired - Lifetime
- 2004-06-10 NZ NZ578264A patent/NZ578264A/en not_active IP Right Cessation
- 2004-06-10 DK DK08166079.7T patent/DK2017265T3/da active
- 2004-06-10 NZ NZ590234A patent/NZ590234A/en not_active IP Right Cessation
- 2004-06-10 PT PT08166079T patent/PT2017265E/pt unknown
- 2004-06-10 PT PT04754996T patent/PT1658269E/pt unknown
- 2004-06-10 WO PCT/US2004/018590 patent/WO2004111009A1/en not_active Ceased
- 2004-06-10 SI SI200431715T patent/SI2017265T1/sl unknown
- 2004-06-10 KR KR1020117017610A patent/KR101150324B1/ko not_active Expired - Fee Related
- 2004-06-14 TW TW093117059A patent/TWI394569B/zh not_active IP Right Cessation
- 2004-06-14 TW TW101107398A patent/TW201300361A/zh unknown
- 2004-06-14 TW TW099119548A patent/TWI366461B/zh not_active IP Right Cessation
2005
- 2005-12-08 IL IL172457A patent/IL172457A/en not_active IP Right Cessation
2009
- 2009-01-14 CY CY20091100044T patent/CY1108713T1/el unknown
2010
- 2010-08-01 IL IL207335A patent/IL207335A/en not_active IP Right Cessation
- 2010-12-17 AU AU2010257277A patent/AU2010257277B2/en not_active Ceased
2011
- 2011-03-07 JP JP2011049274A patent/JP2011153148A/ja active Pending
- 2011-07-28 CY CY20111100738T patent/CY1111945T1/el unknown
- 2011-10-27 IL IL215997A patent/IL215997A0/en unknown
- 2011-10-30 IL IL216046A patent/IL216046A0/en unknown

Also Published As

Publication number	Publication date
TW200509926A (en)	2005-03-16
JP2007500753A (ja)	2007-01-18
DE602004017329D1 (de)	2008-12-04
TWI366461B (en)	2012-06-21
PT2017265E (pt)	2011-07-29
NZ578264A (en)	2011-02-25
WO2004111009A1 (en)	2004-12-23
HK1093727A1 (en)	2007-03-09
NZ543713A (en)	2009-08-28
JP2011153148A (ja)	2011-08-11
KR101138216B1 (ko)	2012-09-05
EP2017265B1 (de)	2011-05-25
IL216046A0 (en)	2011-12-29
MXPA05013550A (es)	2006-04-05
PL1658269T3 (pl)	2009-08-31
EP1658269A1 (de)	2006-05-24
DK1658269T3 (da)	2009-01-12
CY1111945T1 (el)	2015-11-04
PL2017265T3 (pl)	2011-11-30
IL172457A0 (en)	2006-04-10
JP4857113B2 (ja)	2012-01-18
ES2318308T3 (es)	2009-05-01
AU2004247721A1 (en)	2004-12-23
AU2004247721B2 (en)	2011-01-20
TW201300361A (zh)	2013-01-01
ATE411982T1 (de)	2008-11-15
CY1108713T1 (el)	2014-04-09
IL207335A0 (en)	2010-12-30
TW201038269A (en)	2010-11-01
EP1658269B1 (de)	2008-10-22
TWI394569B (zh)	2013-05-01
IL215997A0 (en)	2011-12-29
BRPI0411116A (pt)	2006-07-18
EP2017265A1 (de)	2009-01-21
KR20110089464A (ko)	2011-08-08
SI1658269T1 (sl)	2009-04-30
IL207335A (en)	2012-02-29
DK2017265T3 (da)	2011-09-19
HK1126488A1 (en)	2009-09-04
AU2004247721C1 (en)	2011-12-22
KR20060058769A (ko)	2006-05-30
SI2017265T1 (sl)	2011-09-30
CA2756058A1 (en)	2004-12-23
CN102617464A (zh)	2012-08-01
AU2010257277B2 (en)	2011-08-18
AU2010257277A1 (en)	2011-01-13
KR101150324B1 (ko)	2012-06-13
NZ590234A (en)	2012-07-27
IL172457A (en)	2011-12-29
CA2526872A1 (en)	2004-12-23
CA2526872C (en)	2013-02-05
PT1658269E (pt)	2009-01-09

Legal Events

Date

Code

Title

Description

2011-12-15

UEP

Publication of translation of european patent specification

Ref document number: 2017265

Country of ref document: EP

Publication	Publication Date	Title
ATE510824T1 (de)	2011-06-15	Kondensierte verbindungen, die den vanilloid- rezeptor-subtyp-1 hemmen
IL173269A0 (en)	2006-06-11	Compounds for inflammation and immune-related uses
DE602004017196D1 (de)	2008-11-27	Kondensierte azabicyclische verbindungen, die den vanilloidrezeptorsubtyp 1 (vr1)- rezeptor inhibieren
TW200621232A (en)	2006-07-01	Compounds for inflammation and immune-related uses
BRPI0415185A (pt)	2006-11-28	2h-[1,2,4]triazol[4,3-a]pirazinas substituìdas como inibidores da gsk-3
WO2005092895A3 (en)	2006-03-02	Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists
MXPA04006031A (es)	2004-09-27	Compuestos para el tratamiento de trastornos inflamatorios.
WO2006113552A8 (en)	2007-03-29	Cyanoarylamines
WO2005040121A3 (en)	2005-06-23	Amides that inhibit vanilloid receptor subtype 1 (vr1) receptor
WO2005056535A8 (en)	2006-06-15	1,2,3-triazole amide derivatives as inhibitors of cytokine production
DE60306193D1 (de)	2006-07-27	1,2,3-triazolamid-derivate als cytokininhibitoren
MXPA06000269A (es)	2006-04-07	Tiofenilaminoimidazolinas.
MXPA04005988A (es)	2004-09-27	3,4-dihidro-1h-isoquinolin-2-il-derivados.
PT1167376E (pt)	2004-09-30	Antibioticos macrolidos
WO2006029210A3 (en)	2006-05-04	Acyclic 1,3-diamines and uses therefor
BRPI0511824A (pt)	2007-12-26	radiossensibilizador
GB0327331D0 (en)	2003-12-31	Therapeutic agents